In today’s session EXACT Sciences Corporation (EXAS) registered an unusually high (505) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the October, 2016 call, expecting serious EXAS increase. With 505 contracts traded and 36144 open interest for the Oct, 16 contract, it seems this is a quite bullish bet. The option with symbol: EXAS161021C00020000 closed last at: $0.15 or 57.1% down. About 1.08 million shares traded hands. EXACT Sciences Corporation (NASDAQ:EXAS) has risen 220.29% since March 15, 2016 and is uptrending. It has outperformed by 214.81% the S&P500.
Analysts await EXACT Sciences Corporation (NASDAQ:EXAS) to report earnings on November, 3. They expect $-0.44 EPS, up 2.22% or $0.01 from last year’s $-0.45 per share. After $-0.46 actual EPS reported by EXACT Sciences Corporation for the previous quarter, Wall Street now forecasts -4.35% EPS growth.
EXACT Sciences Corporation (NASDAQ:EXAS) Ratings Coverage
Out of 13 analysts covering EXACT Sciences (NASDAQ:EXAS), 5 rate it a “Buy”, 1 “Sell”, while 7 “Hold”. This means 38% are positive. EXACT Sciences has been the topic of 25 analyst reports since July 24, 2015 according to StockzIntelligence Inc. The company was downgraded on Thursday, February 25 by Roth Capital. The firm has “Buy” rating given on Friday, October 30 by TH Capital. The rating was upgraded by Craig Hallum to “Buy” on Thursday, June 16. Canaccord Genuity maintained the stock with “Buy” rating in Wednesday, October 7 report. The rating was maintained by Goldman Sachs with “Neutral” on Tuesday, October 6. The firm has “Neutral” rating given on Monday, August 15 by Goldman Sachs. Lake Street maintained the shares of EXAS in a report on Tuesday, November 24 with “Hold” rating. Benchmark downgraded it to “Hold” rating and $11 target price in Tuesday, October 6 report. As per Monday, August 24, the company rating was maintained by Canaccord Genuity. The stock has “Sell” rating given by Empire on Friday, February 26.
According to Zacks Investment Research, “EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated.”
Insitutional Activity: The institutional sentiment increased to 1.42 in 2016 Q2. Its up 0.70, from 0.72 in 2016Q1. The ratio improved, as 18 funds sold all EXACT Sciences Corporation shares owned while 41 reduced positions. 30 funds bought stakes while 54 increased positions. They now own 87.89 million shares or 11.45% more from 78.86 million shares in 2016Q1.
Blackrock Advsrs Limited Liability has invested 0% of its portfolio in EXACT Sciences Corporation (NASDAQ:EXAS). Pdts Prtn Limited Company holds 0.22% of its portfolio in EXACT Sciences Corporation (NASDAQ:EXAS) for 229,600 shares. American Research Mgmt Communications holds 0.01% or 2,850 shares in its portfolio. Blair William Il has invested 0.06% of its portfolio in EXACT Sciences Corporation (NASDAQ:EXAS). Metropolitan Life Insur Ny has 0.01% invested in the company for 68,335 shares. Ifc Inc Fl last reported 0.03% of its portfolio in the stock. Blackrock Institutional Communication Na holds 0% or 2.43 million shares in its portfolio. Moreover, Duncker Streett & Com has 0% invested in EXACT Sciences Corporation (NASDAQ:EXAS) for 1,000 shares. Focused Wealth Mgmt has 0% invested in the company for 175 shares. Friess Lc accumulated 54,000 shares or 0.07% of the stock. The Ontario – Canada-based Manufacturers Life Commerce The has invested 0% in EXACT Sciences Corporation (NASDAQ:EXAS). Moreover, Stifel Fincl has 0% invested in EXACT Sciences Corporation (NASDAQ:EXAS) for 20,515 shares. Envestnet Asset Mgmt holds 1,180 shares or 0% of its portfolio. Harvey Capital Mngmt Incorporated has 0.06% invested in the company for 10,000 shares. New York State Common Retirement Fund last reported 0% of its portfolio in the stock.
Insider Transactions: Since July 25, 2016, the stock had 2 buys, and 3 sales for $97,947 net activity. Shares for $109,416 were sold by LIDGARD GRAHAM PETER. ARORA MANEESH had sold 7,359 shares worth $109,060 on Monday, July 25. Zanotti Katherine S bought $60,613 worth of stock. Sterling Lionel bought $90,500 worth of stock or 5,000 shares. Another trade for 1,701 shares valued at $30,584 was sold by COWARD D SCOTT.
Exact Sciences Corporation is a molecular diagnostics firm focused on the early detection and prevention of some forms of cancer. The company has a market cap of $2.30 billion. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline. It currently has negative earnings. It has developed a non invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer.
EXAS Company Profile
Exact Sciences Corporation, incorporated on February 10, 1995, is a molecular diagnostics firm focused on the early detection and prevention of some forms of cancer. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline. The Firm has developed a non invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. The Company’s Cologuard test is a non invasive stool based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody based fecal immunochemical test (FIT). The United States Food and Drug Administration (FDA) approved Cologuard for use as sDNA non-invasive colorectal cancer screening test. Cologuard is available through healthcare providers.
More news for EXACT Sciences Corporation (NASDAQ:EXAS) were recently published by: Prnewswire.com, which released: “Exact Sciences Announces Inclusion of Cologuard® in HEDIS Quality Measures” on October 03, 2016. Livetradingnews.com‘s article titled: “EXACT Sciences Corporation(NASDAQ:EXAS) Trending Below Average” and published on October 18, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.